1.Ninety-four cases of chronic intestinal amebiasis were treated with Milibis® (bismuthoxy p-N-glycolylarsanilate (Wia, Win 1011)) and/or chiniofon, alone or in combination with bismuth subgallate. Sixteen of the patients who relapsed after the first courses of treatment were given a second course of treatment with Milibis®, bringing the total number of treatments to 106.
2.The patients who were freed of Endamoeba histolytica were followed up for an average period of 287 days (range 35 to 543 days, median 344 days). During this period of observation, an average of 10 post-treatment stool specimens per patient were examined.
3.In thirty-two cases chiniofon was used as the principal amebacide. It was used either alone, or with, or alternately with bismuth subgallate. Of the thirty-two cases thus treated fifteen (47 per cent) were cleared of their amebas, and seventeen (53 per cent) relapsed.
4.Milibis® alone, or in combination with chiniofon and/or bismuth subgallate was given to seventy-two persons; sixty-four (89 per cent) of these were immediately cleared of Endamoeba histolytica. Sixty-two (93 per cent) of sixty-seven cases in which chiniofon was not a complicating factor were cleared of E. histolytica for an average observation period of 320 days (median, 433 days).
5.Milibis® also affected other intestinal protozoa. Sixteen of eighteen cases (90 per cent) of Iodamoeba williamsi infections; twenty-three of forty-nine (47 per cent) cases of Endamoeba coli infections and twelve of twenty-nine (41 per cent) cases of Endolimax nana infections were cleared. Milibis® had very little effect on the flagellate Giardia lamblia, but it eliminated Chilomastix mesnili from the three cases observed.
6.The clinical efficacy of Milibis® in the treatment of chronic intestinal amebiasis was confirmed; all of six severe cases which had been resistant to other therapy were cleared with a single course of Milibis®.
7.Milibis® is easy to administer. Treatment does not require hospitalization or confinement to bed. None of the patients treated showed any toxic symptoms or manifestations of intolerance.
Present address, Sterling-Winthrop Research Institute, Rensselaer, New York.
Present address, School of Medicine, University of Arkansas, Little Rock, Arkansas.